BioMarin Pharma (BMRN) Tops Q1 EPS by 43c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 futures muted as investors await big bank earnings; chip weakness weighs
- Oil retreats as Russian diesel supply prospects counter Gulf supply risks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.39 --0%
Revenue Growth %: +31.4%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
PGR, OMID, ACI, More
Revenue Growth %: +31.4%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $1.13, $0.43 better than the analyst estimate of $0.70. Revenue for the quarter came in at $745 million versus the consensus estimate of $741.02 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan (JPM) Misses Q3 EPS by 18c, Misses on Revenue
- Unity Bancorp (UNTY) Tops Q3 EPS by 21c
- Enlight Renewable Engergy (ENLT) PT Lowered to $41 at Mizuho
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
